文献速递小儿眼科与斜弱视眼整形与眼眶

β受体阻滞剂治疗婴幼儿眶周血管瘤:美国眼科学会报告

The Use of β-Blockers for the Treatment of Periocular Hemangiomas in Infants: A Report by the American Academy of Ophthalmology.
PubMed 文献 · Ophthalmology · 2018-08-01

该报告系统综述了β受体阻滞剂治疗婴幼儿眶周血管瘤的文献,共纳入16项研究(3项II级、13项III级证据)。最常见方案为口服普萘洛尔2 mg/kg每日,多数患者病灶缩小,但仅2项系列显示散光改善有统计学意义,弱视影响证据不足;229例中仅2例因严重并发症停药。

要点

  • 口服普萘洛尔2 mg/kg每日为最常见方案,多数患者病灶缩小。
  • β受体阻滞剂可减少散光,但仅2项系列显示有统计学意义。
  • 229例中仅2例因严重并发症需停药,副作用多为轻度。

核心结论

  • 支持局部和全身β受体阻滞剂促进眶周血管瘤消退的安全性和有效性证据有限。
  • 需进一步研究确认最佳剂量和给药途径,以最大程度减少散光和弱视并最小化副作用。

研究设计与样本

  • 美国眼科学会报告,通过PubMed(2018年5月,无日期限制,限英文)和Cochrane Library(无限制)检索,共437条引文,16篇纳入并由方法学家进行证据等级评定。

主要发现

  • 16项研究中无I级证据,3项为II级,13项为III级。
  • 最常见治疗方案为口服普萘洛尔2 mg/kg每日,也使用病灶内和局部β受体阻滞剂。
  • 多数患者病灶大小缩小;β受体阻滞剂 consistently 减少散光,但仅2项系列显示统计学显著。
  • β受体阻滞剂对弱视的影响未充分记录。
  • β受体阻滞剂总体耐受良好,副作用轻微(疲劳、胃肠道不适/腹泻、烦躁/睡眠障碍、轻度喘息、四肢发冷);229例接受β受体阻滞剂的患者中仅2例因严重并发症需停药。

关键数值与推荐

  • 口服普萘洛尔最常用剂量为2 mg/kg每日。
  • 229例接受β受体阻滞剂的患者中仅2例因严重并发症需停止治疗。

临床怎么用

  • β受体阻滞剂可用于促进眶周血管瘤消退,但证据等级有限,需权衡利弊。
  • 使用β受体阻滞剂时应监测散光变化,但弱视影响证据不足。
  • 注意监测轻度副作用如疲劳、胃肠道不适、睡眠障碍、喘息和四肢发冷,严重并发症罕见但需警惕。

局限性

  • 纳入研究无I级证据,多数为III级证据,整体证据质量有限。
  • β受体阻滞剂对弱视的影响未充分记录。
  • 散光减少仅在2项系列中显示统计学显著。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To review the published literature assessing the efficacy of β-blockers for the treatment of periocular hemangioma in infants. METHODS: Literature searches were conducted in May 2018 in PubMed with no date restrictions and limited to studies published in English and in the Cochrane Library database without any restrictions. The combined searches yielded 437 citations. Of these,16 articles were deemed appropriate for inclusion in this assessment and assigned a level of evidence rating by the panel methodologist. RESULTS: None of the 16 studies included in this assessment were rated level I, 3 were rated level II, and 13 were rated level III. The most common treatment regimen was 2 mg/kg daily oral propranolol, but intralesional and topical β-blockers were also used. Treatment effect was most often measured in terms of reduction in the size of the lesions, which occurred in the majority of patients. β-Blockers were consistently shown to reduce astigmatism, but this reduction was shown to be statistically significant in only 2 series. The effect of β-blockers on amblyopia was not adequately documented. β-Blockers were generally well tolerated and had mild side effects (fatigue, gastrointestinal upset/diarrhea, restlessness/sleep disturbances, minor wheezing, and cold extremities). Complications severe enough to require cessation of treatment occurred in only 2 patients out of a total of 229 who received β-blockers. CONCLUSIONS: There is limited evidence to support the safety and efficacy of both topical and systemic β-blockers to promote regression of periocular hemangiomas. Additional research may confirm the best dosage and route of administration to maximize efficacy in reducing induced astigmatism and amblyopia associated with periocular hemangiomas while minimizing side effects.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Hutchinson AK, Kraker RT, Pineles SL, et al. The Use of β-Blockers for the Treatment of Periocular Hemangiomas in Infants: A Report by the American Academy of Ophthalmology. Ophthalmology. 2018. PMID: 30075202. doi:10.1016/j.ophtha.2018.07.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。